Technology | February 28, 2012

AccessClosure Launches MynxGrip Vascular Closure Device

February 28, 2012 — AccessClosure Inc. announced the U.S. Food and Drug Administration (FDA) approval and U.S. launch of the MynxGrip Vascular Closure Device (VCD). Built on the Mynx platform, the MynxGrip VCD offers an active, extravascular and patient-friendly vascular closure solution. MynxGrip adds the proprietary Grip Technology sealant to the distal end of the original Mynx Sealant, resulting in a sealant that actively grips and seals the arteriotomy while expanding and filling the tissue tract, providing a durable hemostasis.

"There has been a long-standing perception that closure devices which 'actively' close the arteriotomy with sutures or clips provide greater security and have better results. Unfortunately the tradeoff for these closure devices has been leaving foreign material permanently behind in the artery," said Stevan Himmelstein, M.D., a cardiologist at Baptist Memorial Hospital-DeSoto in Southaven, Miss. "MynxGrip is the first closure device which provides the benefits of an active, secure close while also being completely extravascular and bioabsorbable."

The MynxGrip Sealant consists of the same polyethylene glycol (PEG) polymer used in the original Mynx Sealant. Grip Technology is a new configuration of PEG that adheres to the contours of the vessel wall, providing active closure of the arteriotomy. The MynxGrip Sealant fully resorbs within 30 days.

"We are extremely excited about the launch of MynxGrip," said Gregory D. Casciaro, president and CEO of AccessClosure Inc. "The total potential worldwide market for vascular closure devices includes an estimated nine million procedures each year. We believe the MynxGrip's enhanced extravascular sealant will be widely adopted by a customer base that seeks an active closure method but does not want to leave anything behind in the vessel."

For more information: www.accessclosure.com

Related Content

Vascade MVP Reduces Time to Ambulation Follow EP Procedures
News | Vascular Closure Devices | November 11, 2018
The Vascade MVP vascular closure system met its endpoints compared to manual compression in a pivotal clinical study...
Technology | Vascular Closure Devices | November 05, 2018
November 2, 2018 — Cordis, a Cardinal Health company, today announced the U.S.
Teleflex Acquires Essential Medical
News | Vascular Closure Devices | October 05, 2018
Teleflex Inc. announced the acquisition of Essential Medical Inc. Based in Exton, Pa., Essential Medical is a privately...
Cardiva Medical Announces Completion of the AMBULATE Pivotal Trial
News | Vascular Closure Devices | May 10, 2018
Cardiva Medical Inc. announced the completion of the AMBULATE pivotal trial, one of several clinical trials in the...
Cardiva Medical Announces $41 Million for AMBULATE Vascular Closure Device Trial
News | Vascular Closure Devices | February 21, 2018
Vascular closure device provider Cardiva Medical announced that the company has closed on $11 million in additional...
The bioresorbable Cordis Mynx Grip vascular closure device seals arteriotomies without use of permanent hardware.

The bioresorbable Cordis MynxGrip vascular closure device seals arteriotomies without use of permanent hardware.

Feature | Vascular Closure Devices | January 22, 2018 | Dave Fornell
While manual compression remains the gold standard for hemostasis of catheterization vascular access site arteriotomi
Vivasure Enrolls First Patient in Frontier IV Clinical Trial
News | Vascular Closure Devices | December 29, 2017
Vivasure Medical announced in October the successful enrollment of the first patient in the Frontier IV clinical study...
Enrollment Completed in U.S. IDE Trial for Manta Large Bore Vascular Closure Device
News | Vascular Closure Devices | December 22, 2017
Essential Medical announced the completion of enrollment in the U.S. pivotal investigational device exemption (IDE)...
Overlay Init